Brad Kahl, MD, discusses the treatment options for patients with indolent lymphomas who are relapsed/refractory.
Brad Kahl, MD
Advertisement
Articles by Brad Kahl, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
3
Petosemtamab Plus Pembrolizumab Improves OS in PD-L1+ HNSCC
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5